SeaStar Medical Scheduled to Present at NobleCon21 Investor Conference on December 3, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Should l Buy ICU?
Source: NASDAQ.COM
Company Presentation: SeaStar Medical Holding Corporation will present at the NobleCon21 Investor Conference on December 3, 2025, discussing its therapeutic platform, commercial progress, and financial positioning.
Product Overview: The company's first commercial product, QUELIMMUNE (SCD-PED) therapy, is FDA-approved for life-threatening acute kidney injury in critically ill pediatric patients, showing promising survival rates in treated patients.
Clinical Trials: SeaStar is conducting a pivotal phase 3 trial, NEUTRALIZE-AKI, for adults with acute kidney injury, and a feasibility study, NEUTRALIZE-CRS, for acute heart failure patients, with positive interim results reported.
Financial Performance: For Q3 2025, SeaStar reported a net revenue increase from QUELIMMUNE sales, a narrowed net loss, and a cash position of $13.8 million, supported by recent equity offerings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICU
Wall Street analysts forecast ICU stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.310
Low
1.00
Averages
1.00
High
1.00
Current: 2.310
Low
1.00
Averages
1.00
High
1.00
About ICU
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SeaStar Medical Releases Survival Data for QUELIMMUNE Therapy
- Significant Survival Rates: The QUELIMMUNE therapy demonstrated a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90 among 21 critically ill pediatric patients, indicating its effectiveness in treating Acute Kidney Injury and sepsis, potentially leading to a significant reduction in patient mortality.
- Favorable Safety Profile: No device-related adverse events or infections were reported during the use of QUELIMMUNE therapy, showcasing its safety in clinical applications and laying a solid foundation for broader adoption in the future.
- Registry Study Support: Preliminary data from the SAVE Registry indicates that the survival rates of QUELIMMUNE therapy align with those observed in FDA-approved registration trials, further validating its clinical efficacy and potentially facilitating wider adoption in medical institutions.
- Expanded Clinical Applications: QUELIMMUNE therapy has been adopted by several renowned children's medical centers in the U.S., expected to provide treatment opportunities for more critically ill pediatric patients, thereby enhancing SeaStar Medical's market share in the pediatric Acute Kidney Injury sector.
See More
SeaStar Medical Expands QUELIMMUNE Adoption, Anticipates $2 Million Revenue in 2026
- Market Expansion: SeaStar Medical plans to broaden QUELIMMUNE adoption to 15 additional top-ranked children's medical centers in 2026, more than doubling its customer base and anticipating approximately $2 million in net product revenue, thereby strengthening its leadership in the ultra-rare pediatric AKI market.
- Clinical Trial Progress: The company aims to accelerate enrollment in the NEUTRALIZE-AKI pivotal trial, expected to complete by the end of 2026, and plans to submit a Premarket Approval application in 2027, which will rapidly drive adoption of the SCD therapy in the adult AKI market upon successful outcomes.
- FDA Fast Track: SeaStar Medical's SCD therapy has received Breakthrough Device Designation from the FDA, designed to expedite treatment for adult AKI and acute heart failure patients, potentially opening up multi-billion-dollar market opportunities for the company.
- Survival Rate Data: The QUELIMMUNE therapy has demonstrated a 76% survival rate at 60 days and 71% at 90 days in clinical applications, with expectations to validate its effectiveness in reducing mortality rates, further solidifying its market position.
See More
SeaStar Medical Announces 1-for-10 Reverse Split, Shares Drop 9.5%
- Reverse Split Impact: SeaStar Medical's announcement of a 1-for-10 reverse split led to a 9.5% drop in pre-market trading, bringing the share price down to $0.21, reflecting market concerns about the company's future prospects.
- Market Reaction: Following the reverse split news, SeaStar's stock price quickly declined, indicating a lack of investor confidence in the company's financial health, which could affect its ability to raise capital and its market image.
- Other Stock Movements: Coincheck Group NV and Ascent Solar Technologies also saw declines in pre-market trading, dropping 11% and 7.6% respectively, indicating a broader bearish sentiment in the market that may influence investor risk appetite.
- Industry Trends: In light of the market's reaction to the reverse split, SeaStar Medical may need to reassess its capital structure and future strategy to restore investor confidence and improve stock performance.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
SeaStar Medical Executes 1-for-10 Reverse Stock Split to Meet Nasdaq Compliance
- Reverse Split Implementation: SeaStar Medical announced a 1-for-10 reverse stock split effective January 5, 2026, aimed at increasing the stock price to comply with Nasdaq's $1 minimum bid requirement, thereby enhancing market confidence and attracting more investors.
- Shareholder Approval: The reverse split plan was approved at the special shareholder meeting on December 18, 2025, reflecting shareholder support and trust in the company's future, which may help improve corporate governance perception.
- Trading Adjustments: Post-split, every 10 shares of common stock will convert into 1 share, with shareholders receiving information regarding their adjusted holdings, ensuring no adverse impact on shareholder rights and further strengthening trust in the company.
- New CUSIP Number: Following the reverse split, the company's stock will trade under the new CUSIP number 81256L302, which will help streamline trading processes and enhance market transparency.
See More
What’s Happening with SeaStar Medical's Stock Today?
Reverse Stock Split Announcement: SeaStar Medical Holding Corporation has initiated a ten-for-one reverse stock split, approved by shareholders, which will take effect on January 2.
Impact on Shares: Following the announcement, SeaStar Medical's shares have dropped by 20.38%, trading at $0.24 at the time of publication.
Share Consolidation Details: The reverse split will consolidate every 10 shares into 1, resulting in approximately 3.8 million shares of common stock outstanding, with no fractional shares issued.
Market Reaction: The significant drop in share price indicates market concerns regarding the company's financial health and the implications of the reverse stock split.
See More
SeaStar Medical Releases Survival Data for QUELIMMUNE Therapy
- Significant Survival Rates: The QUELIMMUNE therapy demonstrated a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90 among 21 critically ill pediatric patients, indicating its effectiveness in treating Acute Kidney Injury and sepsis, potentially leading to a significant reduction in patient mortality.
- Favorable Safety Profile: No device-related adverse events or infections were reported during the use of QUELIMMUNE therapy, showcasing its safety in clinical applications and laying a solid foundation for broader adoption in the future.
- Registry Study Support: Preliminary data from the SAVE Registry indicates that the survival rates of QUELIMMUNE therapy align with those observed in FDA-approved registration trials, further validating its clinical efficacy and potentially facilitating wider adoption in medical institutions.
- Expanded Clinical Applications: QUELIMMUNE therapy has been adopted by several renowned children's medical centers in the U.S., expected to provide treatment opportunities for more critically ill pediatric patients, thereby enhancing SeaStar Medical's market share in the pediatric Acute Kidney Injury sector.
See More
SeaStar Medical Expands QUELIMMUNE Adoption, Anticipates $2 Million Revenue in 2026
- Market Expansion: SeaStar Medical plans to broaden QUELIMMUNE adoption to 15 additional top-ranked children's medical centers in 2026, more than doubling its customer base and anticipating approximately $2 million in net product revenue, thereby strengthening its leadership in the ultra-rare pediatric AKI market.
- Clinical Trial Progress: The company aims to accelerate enrollment in the NEUTRALIZE-AKI pivotal trial, expected to complete by the end of 2026, and plans to submit a Premarket Approval application in 2027, which will rapidly drive adoption of the SCD therapy in the adult AKI market upon successful outcomes.
- FDA Fast Track: SeaStar Medical's SCD therapy has received Breakthrough Device Designation from the FDA, designed to expedite treatment for adult AKI and acute heart failure patients, potentially opening up multi-billion-dollar market opportunities for the company.
- Survival Rate Data: The QUELIMMUNE therapy has demonstrated a 76% survival rate at 60 days and 71% at 90 days in clinical applications, with expectations to validate its effectiveness in reducing mortality rates, further solidifying its market position.
See More
SeaStar Medical Announces 1-for-10 Reverse Split, Shares Drop 9.5%
- Reverse Split Impact: SeaStar Medical's announcement of a 1-for-10 reverse split led to a 9.5% drop in pre-market trading, bringing the share price down to $0.21, reflecting market concerns about the company's future prospects.
- Market Reaction: Following the reverse split news, SeaStar's stock price quickly declined, indicating a lack of investor confidence in the company's financial health, which could affect its ability to raise capital and its market image.
- Other Stock Movements: Coincheck Group NV and Ascent Solar Technologies also saw declines in pre-market trading, dropping 11% and 7.6% respectively, indicating a broader bearish sentiment in the market that may influence investor risk appetite.
- Industry Trends: In light of the market's reaction to the reverse split, SeaStar Medical may need to reassess its capital structure and future strategy to restore investor confidence and improve stock performance.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
SeaStar Medical Executes 1-for-10 Reverse Stock Split to Meet Nasdaq Compliance
- Reverse Split Implementation: SeaStar Medical announced a 1-for-10 reverse stock split effective January 5, 2026, aimed at increasing the stock price to comply with Nasdaq's $1 minimum bid requirement, thereby enhancing market confidence and attracting more investors.
- Shareholder Approval: The reverse split plan was approved at the special shareholder meeting on December 18, 2025, reflecting shareholder support and trust in the company's future, which may help improve corporate governance perception.
- Trading Adjustments: Post-split, every 10 shares of common stock will convert into 1 share, with shareholders receiving information regarding their adjusted holdings, ensuring no adverse impact on shareholder rights and further strengthening trust in the company.
- New CUSIP Number: Following the reverse split, the company's stock will trade under the new CUSIP number 81256L302, which will help streamline trading processes and enhance market transparency.
See More
What’s Happening with SeaStar Medical's Stock Today?
Reverse Stock Split Announcement: SeaStar Medical Holding Corporation has initiated a ten-for-one reverse stock split, approved by shareholders, which will take effect on January 2.
Impact on Shares: Following the announcement, SeaStar Medical's shares have dropped by 20.38%, trading at $0.24 at the time of publication.
Share Consolidation Details: The reverse split will consolidate every 10 shares into 1, resulting in approximately 3.8 million shares of common stock outstanding, with no fractional shares issued.
Market Reaction: The significant drop in share price indicates market concerns regarding the company's financial health and the implications of the reverse stock split.
See More
